Silvia Campana
Overview
Explore the profile of Silvia Campana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, et al.
Ther Adv Respir Dis
. 2025 Feb;
19:17534666251314706.
PMID: 39930791
Background: Cystic fibrosis (CF) is characterized by chronic neutrophilic inflammation in the airways. Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has demonstrably improved clinical outcomes and quality of life in people with CF (pwCF),...
2.
Taccetti G, Terlizzi V, Campana S, Dolce D, Ravenni N, Fevola C, et al.
Eur J Pediatr
. 2024 Dec;
184(1):82.
PMID: 39672981
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections...
3.
Terlizzi V, Ballerini T, Castaldo A, Dolce D, Campana S, Taccetti G, et al.
BMC Pulm Med
. 2024 Sep;
24(1):440.
PMID: 39251945
Background: Recurrent respiratory infections are a leading cause of morbidity and mortality in persons with Cystic Fibrosis (pwCF). Recently, the emergence of Nocardia species as a potential pathogen in CF...
4.
Dolce D, Ravenni N, Fevola C, Francalanci M, Bonomi P, Cavicchi M, et al.
Heliyon
. 2024 Mar;
10(5):e26978.
PMID: 38449646
Background: The upper airways of cystic fibrosis (CF) persons are an evolutionary niche where genetically adapted bacterial strains are selected for lung infection. The microbiological studies conducted up to now...
5.
Francalanci M, Terlizzi V, Fevola C, Di Rosa G, Pierattini V, Roselli E, et al.
Children (Basel)
. 2023 Feb;
10(2).
PMID: 36832382
Background: Improved therapy in CF has led to an overall improvement in nutritional status. The objectives of our study are: to cross-sectionally assess nutritional status and serum levels of fat-soluble...
6.
Bianchimani C, Dolce D, Centrone C, Campana S, Ravenni N, Orioli T, et al.
Int J Neonatal Screen
. 2022 Aug;
8(3).
PMID: 35997436
Pancreatitis-Associated Protein (PAP)-based Cystic Fibrosis (CF) newborn bloodspot screening (NBS) protocols detect less CFTR-Related Metabolic Syndrome (CRMS)/CF Screen Positive, Inconclusive Diagnosis (CFSPID). We prospectively evaluated the impact of PAP as...
7.
Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, et al.
PLoS One
. 2019 Mar;
14(3):e0213497.
PMID: 30901344
Background: Few studies, based on a limited number of patients using non-uniform therapeutic protocols, have analyzed Methicillin-resistant Staphylococcus aureus (MRSA) eradication. Methods: In a randomized multicenter trial conducted on patients...
8.
Manara S, Pasolli E, Dolce D, Ravenni N, Campana S, Armanini F, et al.
Genome Med
. 2018 Nov;
10(1):82.
PMID: 30424799
Background: Staphylococcus aureus is an opportunistic pathogen and a leading cause of nosocomial infections. It can acquire resistance to all the antibiotics that entered the clinics to date, and the...
9.
Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, et al.
J Cyst Fibros
. 2018 Oct;
18(2):212-220.
PMID: 30348610
No abstract available.
10.
Pollini S, Mugnaioli C, Dolce D, Campana S, Neri A, Taccetti G, et al.
J Cyst Fibros
. 2018 Feb;
17(4):470-474.
PMID: 29444761
Background: The significance of chronic lung infection by multidrug-resistant (MDR) pathogens in Cystic Fibrosis (CF) transplanted patients remains controversial, and the available information is overall limited. Here we describe the...